Probiotic Intake and Inflammation in Patients With Chronic Kidney Disease: An Analysis of the CKD-REIN Cohort
Background and AimsLittle is known about the effects of probiotics on inflammation in the context of chronic kidney disease (CKD). We investigated the association between probiotic intake and inflammation in patients with moderate-to-advanced CKD.MethodsWe performed a cross-sectional study of 888 pa...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-03-01
|
| Series: | Frontiers in Nutrition |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnut.2022.772596/full |
| _version_ | 1811275003038007296 |
|---|---|
| author | Sandra Wagner Sandra Wagner Thomas Merkling Marie Metzger Laetitia Koppe Laetitia Koppe Maurice Laville Marie-Christine Boutron-Ruault Luc Frimat Luc Frimat Christian Combe Christian Combe Ziad A. Massy Ziad A. Massy Ziad A. Massy Bénédicte Stengel Bénédicte Stengel Denis Fouque Denis Fouque |
| author_facet | Sandra Wagner Sandra Wagner Thomas Merkling Marie Metzger Laetitia Koppe Laetitia Koppe Maurice Laville Marie-Christine Boutron-Ruault Luc Frimat Luc Frimat Christian Combe Christian Combe Ziad A. Massy Ziad A. Massy Ziad A. Massy Bénédicte Stengel Bénédicte Stengel Denis Fouque Denis Fouque |
| author_sort | Sandra Wagner |
| collection | DOAJ |
| description | Background and AimsLittle is known about the effects of probiotics on inflammation in the context of chronic kidney disease (CKD). We investigated the association between probiotic intake and inflammation in patients with moderate-to-advanced CKD.MethodsWe performed a cross-sectional study of 888 patients with stage 3–5 CKD and data on serum C-reactive protein (CRP) levels and a concomitant food frequency questionnaire. We estimated the odds ratios (ORs) [95% confidence interval (CI)] for various CRP thresholds (>3, >4, >5, >6, and >7 mg/L) associated with three intake categories (no yoghurt, ordinary yoghurt, and probiotics from yoghurts or dietary supplements) and two frequency categories (daily or less than daily).ResultsThe 888 study participants (median age: 70; men: 65%) had a median estimated glomerular filtration rate of 28.6 mL/min/1.73 m2 and a median [interquartile range] CRP level of 3.0 [1.6, 7.0] mg/L. Fifty-seven percent consumed ordinary yoghurt and 30% consumed probiotic yoghurt. The median intake frequency for yoghurt and probiotics was 7 per week. Relative to participants not consuming yoghurt, the ORs [95% CI] for CRP > 6 or >7 mg/L were significantly lower for participants consuming ordinary yoghurt (0.58 [0.37, 0.93] and 0.57 [0.35, 0.91], respectively) and for participants consuming probiotics (0.54 [0.33, 0.9] and 0.48 [0.28, 0.81], respectively), independently of age, sex, body mass index, CKD stage, cardiovascular disease, and fibre, protein and total energy intakes. The ORs were not significantly lower for CRP thresholds >3, >4, and >5 mg/L and were not significantly greater in daily consumers than in occasional consumers.ConclusionWe observed independent associations between the consumption of yoghurt or probiotics and lower levels of inflammation in patients with CKD. There was no evidence of a dose-effect relationship.Clinical Trial Registration[https://www.clinicaltrials.gov/ct2/show/NCT03381950], identifier [NCT03381950]. |
| first_indexed | 2024-04-12T23:29:09Z |
| format | Article |
| id | doaj.art-31fba3a70fb94068af08162289d3be6a |
| institution | Directory Open Access Journal |
| issn | 2296-861X |
| language | English |
| last_indexed | 2024-04-12T23:29:09Z |
| publishDate | 2022-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Nutrition |
| spelling | doaj.art-31fba3a70fb94068af08162289d3be6a2022-12-22T03:12:19ZengFrontiers Media S.A.Frontiers in Nutrition2296-861X2022-03-01910.3389/fnut.2022.772596772596Probiotic Intake and Inflammation in Patients With Chronic Kidney Disease: An Analysis of the CKD-REIN CohortSandra Wagner0Sandra Wagner1Thomas Merkling2Marie Metzger3Laetitia Koppe4Laetitia Koppe5Maurice Laville6Marie-Christine Boutron-Ruault7Luc Frimat8Luc Frimat9Christian Combe10Christian Combe11Ziad A. Massy12Ziad A. Massy13Ziad A. Massy14Bénédicte Stengel15Bénédicte Stengel16Denis Fouque17Denis Fouque18Université de Lorraine, INSERM CIC 1433, Nancy CHRU, Inserm U1116, Nancy, FranceFCRIN INI-CRCT, Nancy, FranceUniversité de Lorraine, INSERM CIC 1433, Nancy CHRU, Inserm U1116, Nancy, FranceCentre de Recherche en Epidémiologie et Santé des Populations (CESP), Univ Paris-Saclay, UVSQ, INSERM, Equipe Epidémiologie Clinique, Villejuif, FranceDépartement de Néphrologie, Hopital Lyon Sud – HCL, Pierre-Bénite, FranceUniversité de Lyon, CarMeN Laboratory, INSA-Lyon, INSERM U1060, INRA, Université Claude Bernard Lyon 1, Villeurbanne, FranceUniversité de Lyon, CarMeN Laboratory, INSA-Lyon, INSERM U1060, INRA, Université Claude Bernard Lyon 1, Villeurbanne, FranceCentre de Recherche en Epidémiologie et Santé des Populations (CESP), Université Paris-Saclay, UVSQ, INSERM, Gustave Roussy, Equipe Exposome-Hérédité, Villejuif, FranceEA4360 APEMAC, Université de Lorraine, Université Paris Descartes, Nancy, FranceDépartement de Néphrologie, CHU de Nancy, Vandoeuvre-lès-Nancy, FranceService de Néphrologie-Transplantation-Dialyse-Aphérèse, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France0INSERM, U1026, Université Bordeaux Segalen, Bordeaux, FranceFCRIN INI-CRCT, Nancy, FranceCentre de Recherche en Epidémiologie et Santé des Populations (CESP), Univ Paris-Saclay, UVSQ, INSERM, Equipe Epidémiologie Clinique, Villejuif, France1Service de Néphrologie, Hôpital Ambroise Paré, APHP, Paris, FranceFCRIN INI-CRCT, Nancy, FranceCentre de Recherche en Epidémiologie et Santé des Populations (CESP), Univ Paris-Saclay, UVSQ, INSERM, Equipe Epidémiologie Clinique, Villejuif, FranceDépartement de Néphrologie, Hopital Lyon Sud – HCL, Pierre-Bénite, FranceUniversité de Lyon, CarMeN Laboratory, INSA-Lyon, INSERM U1060, INRA, Université Claude Bernard Lyon 1, Villeurbanne, FranceBackground and AimsLittle is known about the effects of probiotics on inflammation in the context of chronic kidney disease (CKD). We investigated the association between probiotic intake and inflammation in patients with moderate-to-advanced CKD.MethodsWe performed a cross-sectional study of 888 patients with stage 3–5 CKD and data on serum C-reactive protein (CRP) levels and a concomitant food frequency questionnaire. We estimated the odds ratios (ORs) [95% confidence interval (CI)] for various CRP thresholds (>3, >4, >5, >6, and >7 mg/L) associated with three intake categories (no yoghurt, ordinary yoghurt, and probiotics from yoghurts or dietary supplements) and two frequency categories (daily or less than daily).ResultsThe 888 study participants (median age: 70; men: 65%) had a median estimated glomerular filtration rate of 28.6 mL/min/1.73 m2 and a median [interquartile range] CRP level of 3.0 [1.6, 7.0] mg/L. Fifty-seven percent consumed ordinary yoghurt and 30% consumed probiotic yoghurt. The median intake frequency for yoghurt and probiotics was 7 per week. Relative to participants not consuming yoghurt, the ORs [95% CI] for CRP > 6 or >7 mg/L were significantly lower for participants consuming ordinary yoghurt (0.58 [0.37, 0.93] and 0.57 [0.35, 0.91], respectively) and for participants consuming probiotics (0.54 [0.33, 0.9] and 0.48 [0.28, 0.81], respectively), independently of age, sex, body mass index, CKD stage, cardiovascular disease, and fibre, protein and total energy intakes. The ORs were not significantly lower for CRP thresholds >3, >4, and >5 mg/L and were not significantly greater in daily consumers than in occasional consumers.ConclusionWe observed independent associations between the consumption of yoghurt or probiotics and lower levels of inflammation in patients with CKD. There was no evidence of a dose-effect relationship.Clinical Trial Registration[https://www.clinicaltrials.gov/ct2/show/NCT03381950], identifier [NCT03381950].https://www.frontiersin.org/articles/10.3389/fnut.2022.772596/fullinflammationC-reactive proteinyoghurtprobioticchronic kidney diseaseepidemiology |
| spellingShingle | Sandra Wagner Sandra Wagner Thomas Merkling Marie Metzger Laetitia Koppe Laetitia Koppe Maurice Laville Marie-Christine Boutron-Ruault Luc Frimat Luc Frimat Christian Combe Christian Combe Ziad A. Massy Ziad A. Massy Ziad A. Massy Bénédicte Stengel Bénédicte Stengel Denis Fouque Denis Fouque Probiotic Intake and Inflammation in Patients With Chronic Kidney Disease: An Analysis of the CKD-REIN Cohort Frontiers in Nutrition inflammation C-reactive protein yoghurt probiotic chronic kidney disease epidemiology |
| title | Probiotic Intake and Inflammation in Patients With Chronic Kidney Disease: An Analysis of the CKD-REIN Cohort |
| title_full | Probiotic Intake and Inflammation in Patients With Chronic Kidney Disease: An Analysis of the CKD-REIN Cohort |
| title_fullStr | Probiotic Intake and Inflammation in Patients With Chronic Kidney Disease: An Analysis of the CKD-REIN Cohort |
| title_full_unstemmed | Probiotic Intake and Inflammation in Patients With Chronic Kidney Disease: An Analysis of the CKD-REIN Cohort |
| title_short | Probiotic Intake and Inflammation in Patients With Chronic Kidney Disease: An Analysis of the CKD-REIN Cohort |
| title_sort | probiotic intake and inflammation in patients with chronic kidney disease an analysis of the ckd rein cohort |
| topic | inflammation C-reactive protein yoghurt probiotic chronic kidney disease epidemiology |
| url | https://www.frontiersin.org/articles/10.3389/fnut.2022.772596/full |
| work_keys_str_mv | AT sandrawagner probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort AT sandrawagner probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort AT thomasmerkling probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort AT mariemetzger probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort AT laetitiakoppe probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort AT laetitiakoppe probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort AT mauricelaville probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort AT mariechristineboutronruault probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort AT lucfrimat probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort AT lucfrimat probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort AT christiancombe probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort AT christiancombe probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort AT ziadamassy probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort AT ziadamassy probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort AT ziadamassy probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort AT benedictestengel probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort AT benedictestengel probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort AT denisfouque probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort AT denisfouque probioticintakeandinflammationinpatientswithchronickidneydiseaseananalysisoftheckdreincohort |